Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer
- Written by PR Newswire
SHANGHAI, May 13, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced the progress of the clinical study of its novel Nectin-4-targeting ADC (R&D code: 9MW2821) for triple-negative breast cancer.
Based on 9MW2821's current ongoing monotherapy clinical data, in 20...
Read more: Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer














